Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 5/20 | 0.39 |
| ▸ | ADH1A | P07327 | 5/20 | 0.39 |
| ▸ | ADH1C | P00326 | 4/20 | 0.39 |
| ▸ | ADH7 | P40394 | 3/20 | 0.39 |
| ▸ | ADH4 | P08319 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7687409 | 0.95 | ADH1B (0.39) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL7687869 | 0.93 | ADH1A (0.41) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL426041 | 0.90 | — | — | |
| SCHEMBL636442 | 0.69 | — | — | |
| SCHEMBL4923567 | 0.69 | — | — | |
| SCHEMBL3923881 | 0.67 | — | — | |
| SCHEMBL7688909 | 0.65 | ADH1B (0.43) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL17322191 | 0.65 | CA1 (0.42) | ADH1BADH1AADH1CADH4 | |
| SCHEMBL426023 | 0.65 | — | — | |
| SCHEMBL13806350 | 0.65 | ACACB (0.32) | ADH1BADH1AADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4364739-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | OSAKA UNIVERSITY (JP) | 2024-05-08 | — | — | EP | disclosed |
| US-11976062-B2 | Benzisoxazole compound | OSAKA UNIVERSITY (JP) | 2024-05-07 | — | — | US | disclosed |
| EP-3789383-B9 | INHIBITORS OF THE TRPC3 OR TRPC6 CHANNEL | UNIV OSAKA (JP) | 2024-02-28 | — | — | EP | disclosed |
| CN-117580577-A | Pharmaceutical composition for preventing and/or treating kidney injury and autophagy activator | 国立大学法人大阪大学 | 2024-02-20 | — | — | CN | disclosed |
| EP-3789383-B1 | INHIBITORS OF THE TRPC3 OR TRPC6 CHANNEL | UNIV OSAKA (JP) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023163203-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE | 国立大学法人大阪大学 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023132208-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | 国立大学法人大阪大学 | 2023-07-13 | — | — | WO | disclosed |
| US-20230114195-A1 | BENZISOXAZOLE COMPOUND | KYOTO UNIVERSITY (JP) | 2023-04-13 | — | — | US | disclosed |
| US-11548882-B2 | Benzisoxazole compound | OSAKA UNIVERSITY (JP) | 2023-01-10 | — | — | US | disclosed |
| WO-2023276828-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | 国立大学法人大阪大学 | 2023-01-05 | — | — | WO | disclosed |
| WO-2021079962-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF HEARING LOSS | 国立大学法人大阪大学 | 2021-04-29 | — | — | WO | disclosed |
| EP-3789383-A1 | BENZISOXAZOLE COMPOUND | Osaka University (JP) | 2021-03-10 | — | — | EP | disclosed |
| CN-112204017-A | Benzisoxazole compounds | 国立大学法人大阪大学 | 2021-01-08 | — | — | CN | disclosed |
| US-20150315146-A1 | USE OF SUBSTITUTED 1-(ARYL ETHYNYL)-, 1-(HETEROARYL ETHYNYL)-, 1-(HETEROCYCLYL ETHYNYL)- AND 1-(CYCLOALKENYLETHYNYL)-BICYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-11-05 | — | — | US | disclosed |
| EP-2928297-A1 | USE OF SUBSTITUTED 1-(ARYL ETHYNYL)-, 1-(HETEROARYL ETHYNYL)-, 1-(HETEROCYCLYL ETHYNYL)- AND 1-(CYLOALKENYL ETHYNYL)-BICYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | Bayer CropScience AG (DE) | 2015-10-14 | — | — | EP | disclosed |
| US-8835461-B2 | Substituted 3-hydroxy-4-pyridone derivative | SHIONOGI & CO., LTD. (JP) | 2014-09-16 | — | — | US | disclosed |
| WO-2014086723-A1 | USE OF SUBSTITUTED 1-(ARYL ETHYNYL)-, 1-(HETEROARYL ETHYNYL)-, 1-(HETEROCYCLYL ETHYNYL)- AND 1-(CYLOALKENYL ETHYNYL)-BICYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2014-06-12 | — | — | WO | disclosed |
| EP-2412708-A1 | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE | Shionogi&Co., Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20120022255-A1 | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| WO-2002000622-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976062-B2 | Benzisoxazole compound | CBR1, CYP2S1, CYP2E1 | ADH1B 1212/4885ADH1A 714/4885ADH1C 1167/4885 |
| US-20120022255-A1 | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE | ENDOD1, CNBP, DPP4 | ADH1B 1462/4885ADH1A 1954/4885ADH1C 3036/4885 |
| US-11548882-B2 | Benzisoxazole compound | CBR1, CYP2S1, CYP2E1 | ADH1B 1207/4885ADH1A 712/4885ADH1C 1170/4885 |
| US-20150315146-A1 | USE OF SUBSTITUTED 1-(ARYL ETHYNYL)-, 1-(HETEROARYL ETHYNYL)-, 1-(HETEROCYCLYL ETHYNYL)- AND 1-(CYCLOALKENYLETHYNYL)-BICYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | AAK1, SYMPK, CBR1 | ADH1B 3522/4885ADH1A 946/4885ADH1C 882/4885 |
| US-20230114195-A1 | BENZISOXAZOLE COMPOUND | CBR1, CYP2S1, CYP2E1 | ADH1B 1196/4885ADH1A 694/4885ADH1C 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.